Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo aims to shrink head and neck tumors before surgery

NCT ID NCT07400094

Disease control Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving a combination of the immunotherapy drug camrelizumab and two chemotherapy drugs (paclitaxel and carboplatin) before surgery can improve outcomes for people with advanced oral cavity or larynx cancer. Fifty participants will receive three cycles of the drug combo, then undergo surgery to remove the tumor. The study will measure how many tumors completely disappear or shrink significantly, and track survival over three years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
camrelizumab (an immunotherapy drug) combined with paclitaxel and carboplatin (chemotherapy drugs)
What this could lead to
If successful, this approach could shrink tumors before surgery, potentially improving long-term survival and reducing the need for additional treatments after surgery.
What could go wrong
This is a small, early-phase study (50 people) with no control group, so results may not be definitive. Immunotherapy can cause serious side effects like inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed squamous cell carcinoma of the oral cavity and/or larynx, Stage III-IVA (cT1-2N1-2M0, cT3-4aN0-2M0) * Resectable disease planned for surgical treatment * Age 18-75 years * No prior antitumor therapy for the current diagnosis * Tumor sample available for PD-L1 expression assessment * No other malignancies in anamnesis (except basal cell carcinoma of skin and carcinoma in situ of cervix) * Absence of comorbidities preventing systemic chemotherapy and immunotherapy Exclusion Criteria: * Patient refusal to undergo planned treatment * Protocol violations not related to medical indications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Laryngeal neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma laryngeal neoplasm laryngeal squamous cell carcinoma Mouth Neoplasms oral cavity neoplasm oral cavity squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Laryngeal neoplasms Oral cavity neoplasm Squamous cell carcinoma of head and neck

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • P.A. Hertsen Moscow Oncology Research Institute

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.